Blurbs

Teva Pharmaceutical Industries Ltd (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?

Mizuho’s Irina Rivkind reflects on how much Teva’s cost cutting compare to expectations; The missing puzzle piece – revenue guidance.

Valeant Pharmaceuticals Intl Inc (VRX) Bear Boosts Price Target Amid Solid Turnaround Efforts

Mizuho’s Irina Rivkind Koffler cannot “justify” changing her rating on Valeant. Instead, the analyst lifts her price target by 40%; Here’s why.

J.P. Morgan Bets M&A Opportunities Could Drive Big Upside To Biotech Sector In 2018

J.P. Morgan’s Cory Kasimov is out with a research report highlighting what should be a promising 2018 for the Biotech group.

Walt Disney (DIS) Aims to Win the Race for Premium Content

Canaccord’s Aravinda Galappatthige weighs in on the greater implications in a post-Disney/Fox merger.

Valeant Pharmaceuticals Intl Inc (VRX) Has A New Bear In Town

J.P. Morgan’s Chris Schott is raising the ultimate red flag on Valeant with a downgrade that has sent shares on a 6% dive today.

Trading Cable Heading into the New Year

The GBP/USD currency pair is holding at the critical 1.34 level. The cable has a …

Veeva Systems Is Worth the Buy Longer-Term, Says Canaccord

While Veeva Systems (NYSE:VEEV) shares are dipping close to 7% after a print that failed …

This Analyst Finds Nutanix Well-Positioned in the Enterprise Market Following Raymond James Tech Conference

After Nutanix Inc (NASDAQ:NTNX) CFO Duston Williams discussed the company’s transition to software taking center …

Does Helios and Matheson Analytics’ Selloff Represents a Buying Opportunity?

Helios and Matheson Analytics (NASDAQ:HMNY) is an IT consulting company — but one with a …

Guggenheim Storms Into the Dermatology Space; Initiates Buy on Revance Therapeutics, Inc. (RVNC)

Guggenheim analyst Rohit Vanjani has initiated coverage of the dermatology space, announcing ratings on four …